Today we're delivering a fascinating message from Oxford Club Chief Income Strategist Marc Lichtenfeld. He's uncovered a rare situation in the markets... Dear Reader, Why would a top coronavirus-fighting biotech rescind a rare, lucrative status it received from the FDA? Its reason is a very good one... But before we get into it, let me first show you how POWERFUL this special designation can be for investors... In November 2016, AbbVie won the same FDA designation for a Crohn's disease treatment. I recommended AbbVie to my VIP readers shortly thereafter, in early 2017... And they were able to close out gains of 2,381% on a special play in just a ten-month period... Enough to turn every $10K into $248,100. One recently retired gentleman said he made $1.3 MILLION on that 2,381% trade in under a year... and celebrated the biggest win of his life by taking his entire family on a vacation to Italy. But AbbVie's not the only company that took off after receiving this special designation... Vertex Pharmaceuticals received the status for its cystic fibrosis treatment on December 20, 2006. The stock has soared from $35 at that point to more than $230 today. 
Alexion Pharmaceuticals won this status in 2009 for its drug Soliris, used to treat a rare kidney disease. Alexion ran up from about $22 to $200. 
So obviously there's a tremendous amount of potential profit on the line with this designation. And recently, my No.1 biotech company won the coveted status in its quest for a COVID-19 solution. CNBC says my top biotech "could be the best bet in the race to cure coronavirus." Financial Times says testing of the drug in patients "has shown early positive signs." And The Washington Post reported, "Two-thirds of severely ill patients showed some improvement when treated with the antiviral medicine." So why would the company rescind the special FDA status as it continues to make progress with its COVID-19 drug? The simple, smart reason is here. To your health and wealth, Marc Lichtenfeld
Chief Income Strategist, The Oxford Club P.S. It's clear that this company is committed to getting its drug developed as quickly as possible. And if its prized COVID-19 drug wins out... And provides a true treatment... The company will be championed worldwide. Get the full details here. | 
No comments:
Post a Comment